Data from the phase 3 Mandala trial shows that a fixed dose of albuterol and budesonide when met its primary endpoint by demonstrating statistically significant and clinically meaningful reductions in the risk of severe exacerbations compared to albuterol, when used as a rescue medicine. “This represents a paradigm shift in the treatment of asthma. We see this combination treatment, which